Chart for the ongoing monitoring of lisdexamfetamine dimesylate therapy

This chart is designed to support you in the ongoing monitoring of lisdexamfetamine dimesylate therapy in patients with attention-deficit/hyperactivity disorder (ADHD).

As detailed in the summary of product characteristics (SmPC) and in the product prescribing information, growth, psychiatric and cardiovascular status should be monitored regularly in patients receiving lisdexamfetamine dimesylate. It is recommended that this chart be used in conjunction with the Tyvense® SmPC **(click here to view)**. Importantly:

- Blood pressure and heart rate (pulse) should be recorded on a centile chart at each adjustment of dose and then at least every six months
- Height, weight and appetite should be recorded at least every six months with maintenance of a growth chart
- Development of *de novo* or worsening of pre-existing psychiatric disorders should be monitored at each adjustment of dose and then at least every six months and at every visit
- Patients should also be monitored for the risk of diversion, misuse and abuse of lisdexamfetamine dimesylate

Please download and print this chart prior to your consultation. It will not be possible for you to store any patient-specific information on the website. The completed chart can be documented within the patient's records.

Date of initial assessment:	
Patient name:	
Date of birth:	
Age:	Gender:

	Baseline, prior to beginning lisdexamfetamine dimesylate treatment	Subsequent appointments							
Date of assessment									
Blood pressure*									
Heart rate (pulse) (bpm)*									
Height (cm)**									
Body weight (kg)**									
Appetite**									

*Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every six months
**Height, weight and appetite should be recorded at least every six months with maintenance of a growth chart

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions

Please report any suspected adverse event(s) to Takeda at AE.GBR-IRL@takeda.com and HPRA Pharmacovigilance at www.hpra.ie

This checklist is intended for use by healthcare professionals in Ireland only, in conjunction with the Tyvense® SmPC.
This tool was developed by Takeda. EXA/IE/ELVS/0002 Date of preparation: December 2021